256417-11-5

Basic information

• Product Name: 2,3-Difluoro-4-methoxybenzaldehyde
• Synonyms: 2,3-Difluoro-4-methoxybenzaldehyde
• CAS NO: 256417-11-5
• Molecular Formula: C₈H₆F₂O₂
• Molecular Weight: 172.13
• Mol File: 256417-11-5.mol

Chemical Properties

• Melting Point: 65-66 °C
• Boiling Point: 235.7°Cat760mmHg
• Flash Point: 93.7°C
• Appearance: /
• Density: 1.289g/cm³
• Vapor Pressure: 0.0494mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: 2-8°C
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2,3-Difluoro-4-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Difluoro-4-methoxybenzaldehyde(256417-11-5)
• EPA Substance Registry System: 2,3-Difluoro-4-methoxybenzaldehyde(256417-11-5)

Safety Data

• Hazard Codes: Xi
• TSCA: No
• Hazardous Substances Data: 256417-11-5(Hazardous Substances Data)

Usage

Uses

use in drug synthesis.

InChI:InChI=1/C8H6F2O2/c1-12-6-3-2-5(4-11)7(9)8(6)10/h2-4H,1H3

Upstream product

• 4885-02-3 Dichloromethyl methyl ether 
• 134364-69-5 2.3-difluoroanisole 
• 594-19-4 tert.-butyl lithium 
• 68-12-2 N,N-dimethyl-formamide 
• 1010801-00-9 2,3-difluoro-4-((triisopropylsilyl)oxy)benzaldehyde 
• 1010800-88-0 2,3-difluoro-4-((triisopropylsilyl)oxy)benzoic acid 
• 749230-30-6 (2,3-difluorophenoxy)triisopropylsilane 
• 676500-39-3 2,3-difluoro-4-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 6418-38-8 2,3-difluorophenol 

Downstream Products

• 689258-07-9 (2E)-3-(2,3-difluoro-4-methoxyphenyl)-N-methoxy-N-methylprop-2-enamide 
• 1010801-01-0 methyl 3-(2,3-difluoro-4-methoxyphenyl)-3-hydroxy-2,2-dimethylpropanoate 
• 676500-39-3 2,3-difluoro-4-hydroxybenzaldehyde 
• 1010801-02-1 methyl 3-(2,3-difluoro-4-methoxyphenyl)-2,2-dimethyl-3-oxopropanoate 
• 1010801-04-3 3-(2,3-difluoro-4-hydroxyphenyl)-4,4-dimethyl-1H-pyrazol-5(4H)-one 
• 1010802-00-2 C₂₉H₂₉F₅N₆O₄ 
• 1093857-65-8 2-[4-[2,3-Difluoro-4-(4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)phenoxy]butyl]-5-(8-methoxy-2-trifluoromethylimidazo[1,2-a]pyridin-5-yl)-4,4-dimethyl-2,4-dihydro-pyrazol-3-one 
• 1093857-58-9 2-[4-[2,3-difluoro-4-(4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-3-yl)phenoxy]butyl]-5-(4-methoxy-2-trifluoromethylbenzo[d]thiazol-7-yl)-4,4-dimethyl-2,4-dihydro-pyrazol-3-one 
• 1010801-03-2 5-(2,3-Difluoro-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydropyrazol-3-one 
• 1355330-17-4 5-(2,3-difluoro-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole 
• 931108-29-1 1-ethynyl-2,3-difluoro-4-methoxybenzene 

Relevant articles and documents

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(-)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-4-yl) -5-methyl-4,5-dihydropyridazin-3(2H)-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory activity and promises as a combined bronchodilatory/anti- inflammatory agent. N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition. Addition of a 6-aryl-4,5-dihydropyridazin-3(2H)-one extension to the N-alkyl group facilitates both enhancement of PDE4-inhibitory activity and restoration of potent PDE3 inhibition. Both dihydropyridazinone rings, in the core and extension, can be replaced by achiral 4,4-dimethylpyrazolone subunits and the core pyrazolopyridine by isosteric bicyclic heteroaromatics. In combination, these modifications afford potent dual PDE3/4 inhibitors that suppress histamine-induced bronchoconstriction in vivo and exhibit promising anti-inflammatory activity via intratracheal administration.

Halogenated analogs of 1′-acetoxychavicol acetate, Rev-export inhibitor from Alpinia galanga, designed from mechanism of action

In the course of search for the robust analogs of 1′-acetoxychavicol acetate (ACA, 1), the Rev-export inhibitor from the medicinal plant Alpinia galanga, we clarified formation of the quinone methide intermediate ii to be essential for exerting the inhibi

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives

The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.

Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4

The synthesis of a series of fluorinate d benzaldehydes and their use in the Wittig synthesis of fluoro-substituted stilbenes is described. 3,5-Difluoro-4-hydroxybenzaldehyde (6) and 3-fluoro-4-methoxybenzaldehyde (11) are prepared by Duff formylation of 3,5-difluorophenol and 2-fluoroanisole, respectively. 2-Methoxy-3,4-difluorobenzaldehyde was obtained by Friedel-Crafts formylation of 2,3-difluoroanisole with α,α-dichloromethyl methyl ether. The aldehydes were used to make a series of fluorinated analogues of the anticancer combretastatins A-1, A-2 and A-4. The in vitro anticancer properties of the fluoro combretastatins are reported. The most active fluoro analogue 3-deoxy-3-fluoro-combretastatin A-4 (Z-2) retains the potent cell growth inhibitory properties of CA-4.